Androgen Deprivation

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

By

The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.

Osteoporosis May Be Present Before Prostate Cancer ADT

Osteoporosis May Be Present Before Prostate Cancer ADT

By

Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.

PSA Nadir in ADT Recipients: The Lower, The Better

PSA Nadir in ADT Recipients: The Lower, The Better

By

The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.

Primary ADT Not Beneficial in Most Cases of Early Prostate Cancer

Primary ADT Not Beneficial in Most Cases of Early Prostate Cancer

By

The treatment, however, is associated with a decreased risk of all-cause mortality in men at high risk of disease progression.

Exercise Eases Adverse Effects of Androgen-Deprivation Therapy

By

It is beneficial in terms of muscle strength, cardiorespiratory fitness, functional task performance, lean body mass, and fatigue.

Prostate Cancer ADT Raises Hip Fracture Risk

By

Liberal use of androgen deprivation therapy likely gave prostate cancer patients a fracture risk comparable to that of the cancer itself.

Prostate Cancer ADT Found to Boost Acute Kidney Injury Risk

By

Acute kidney injury was most likely to develop in men receiving combined androgen blockade.

Very Low Testosterone Key During Continuous ADT

By

Study reveals lower risk of developing castrate-resistant prostate cancer.

Integrated PCa Care Improves IMRT Efficiency

Integrated PCa Care Improves IMRT Efficiency

Integrated prostate cancer centers have greater use of intensity modulated radiation therapy.

PSA Relapse May Be An Unreliable Post-ADT Endpoint

By

Testosterone takes a long time to recover, so PSA levels in prostate cancer patients may remain low.

Managing Bone Loss Associated with Androgen Deprivation Therapy

While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.

Continuous Superior to Intermittent ADT, Study Finds

By

A large, international trial has found intermittent ADT is not equivalent to continuous ADT.

Sildenafil Preserves Erectile Function in Radiotherapy Patients

By

Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.

Continuous ADT Use for Prostate Cancer Quantified

By

Nearly 189,000 men with nonmetastatic disease are receiving continuous ADT for six months or more, researchers estimate.

ADT-Related Fracture Boosts Mortality Risk

By

Men with prostate cancer receiving ADT who experience a fracture may have a 1.38-fold higher mortality risk.

Hormonal ADT for Prostate Cancer Ups Heart Attack, Stroke Risk

By

Risk is unaffected by orchiectomy, large Danish study finds.

ADT for Prostate Cancer May Raise Biliary Disease Risk

By

Elevated risk of gallbladder problems found with use of GnRH agonists.

Exercise Maintains Sexual Interest During Androgen Suppression

By

Researchers concluded that exercise be considered as an adjunctive therapy in men undergoing androgen suppression.

Calcium for ADT Bone Loss May Worsen PCa: An Interview with Gary G. Schwartz, PhD, MPH

Calcium for ADT Bone Loss May Worsen PCa: An Interview with Gary G. Schwartz, PhD, MPH

By

Considering that bone loss is a known side effect of ADT for men with PCa, it might seem logical that calcium and vitamin D supplementation would help manage this consequence.

Intermittent and Continuous ADT Offer Similar Survival

By

The estimated seven-year cumulative rates of prostate cancer-related death were 18% and 15%, respectively, for intermittent and continuous androgen suppression.

ADT Plus Radiation Improves Outcomes in PCa Patients

By

New data indicate a sustained and substantial overall and disease-specific survival benefit associated with androgen deprivation therapy (ADT) plus radiation therapy among patients with locally advanced prostate cancer.

Have you ever placed a prostate cancer patient on intermittent rather than continuous androgen deprivation therapy?

By

Recent studies have looked at the use of intermittent ADT as way to spare prostate cancer (PCa) patients some of the adverse effects associated with continuous ADT.

ADT Prior to Salvage Cryo Does Not Improve BFS

By

Androgen deprivation therapy (ADT) prior to salvage cryotherapy does not improve biochemical-free survival (BFS) at five years, according to data presented at the American Urological Association 2012 annual meeting.

Radiotherapy Added to ADT Beneficial

By

Adding radiotherapy to androgen deprivation therapy (ADT) improves outcomes in patients with locally advanced prostate cancer (PCa) and can be considered a standard treatment option.

BMD Loss Occurs Early in Androgen Deprivation Therapy

BMD Loss Occurs Early in Androgen Deprivation Therapy

Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer

ADT for Prostate Cancer Does Not Boost Cardiovascular Mortality

By

Use of short-course androgen deprivation therapy (ADT) may improve overall and disease-specific survival but does not appear to increase cardiovascular mortality in men with clinically-localized prostate cancer.

Triple-Regimen Benefits Men with Intermediate-Risk Prostate Cancer

By

Combined external beam radiation therapy (EBRT) with a brachytherapy boost plus androgen deprivation therapy (ADT) is associated with excellent disease-free survival among men with intermediate-risk prostate cancer (PCa), researchers reported.

ADT Use Declining, Patterns of Use Changing

By

Initiation of androgen deprivation therapy (ADT) for prostate cancer (PCa) is declining and patterns of use are changing, according to recently published data from a Canadian study.

Obesity Raises Metastasis Risk in Prostate Cancer Patients on ADT

By

Obesity is associated with an increased risk for prostate cancer (PCa) progression among PCa patients treated with androgen deprivation therapy (ADT) after radical prostatectomy, according to a study.

Drug Cleared for Treating ADT-Related Bone Loss in Prostate Cancer Patients

By

The FDA has approved denosumab (Prolia) as a treatment to increase bone mass in prostate cancer patients at high risk for fracture undergoing androgen deprivation therapy (ADT) and women with breast cancer at high risk for fracture who are receiving aromatase inhibitor therapy.

Sign Up for Free e-newsletters